Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc submitted a Form 6-K detailing routine activity under its existing share-buyback programme. Acting through Merrill Lynch International, the company repurchased 473,254 ordinary shares on 19 June 2025 at prices ranging from 1,424.00p to 1,441.50p, producing a volume-weighted average price of 1,434.72p.
Since the mandate began on 4 June 2025, 4,664,836 shares have been acquired. The latest transaction lifts treasury holdings to 222,799,219 shares, equivalent to 5.44 % of total voting rights. Shares outstanding (excluding treasury) now stand at 4,092,502,370, which is also the updated denominator for disclosure threshold calculations under the FCA’s Disclosure Guidance & Transparency Rules.
The filing includes a granular trade log for London Stock Exchange executions; no purchases occurred on CBOE venues. All shares will be held in treasury and may be used for future capital management purposes such as employee share plans or cancellation.
GSK plc filed a Form 6-K detailing daily activity under its ongoing share repurchase programme. On 18 June 2025, the company bought 468,255 ordinary shares (31 ⅔ p nominal value) through its broker Merrill Lynch International. Purchase prices ranged from 1,444.00 p to 1,469.50 p with a volume-weighted average of 1,454.83 p per share.
The transaction forms part of the non-discretionary buyback mandate announced on 4 June 2025. Cumulatively since that date, 4,191,582 shares have been repurchased.
Following the latest purchase, GSK holds 222,325,965 shares in treasury, representing 5.43 % of voting rights. Shares outstanding excluding treasury now total 4,092,975,624; this figure is the denominator shareholders should use for FCA DTR notifications.
No financial performance metrics or strategic changes were disclosed; the filing is limited to share buyback execution details.